Novartis AG Current Value Added Tax Receivables
Novartis AG (NVS) had Current Value Added Tax Receivables of $550.00 million as of 2025-12-31, per its 20-F filed 2026-02-04.
Financial Statements › Notes › Receivables
ifrs-full:CurrentValueAddedTaxReceivables · last filed 2026-02-04
- 2025-12-31: Current Value Added Tax Receivables $550.00M.
- 2024-12-31: Current Value Added Tax Receivables $478.00M.
- 2023-12-31: Current Value Added Tax Receivables $462.00M.
- 2022-12-31: Current Value Added Tax Receivables $509.00M.
| Period end | Current Value Added Tax Receivables |
|---|---|
| 2025-12-31 | $550.00M 20-F · filed 2026-02-04 |
| 2024-12-31 | $478.00M 20-F · filed 2026-02-04 |
| 2023-12-31 | $462.00M 20-F · filed 2025-01-31 |
| 2022-12-31 | $509.00M 20-F · filed 2024-01-31 |
| 2021-12-31 | $487.00M 20-F/A · filed 2023-05-15 |
| 2020-12-31 | $544.00M 20-F · filed 2022-02-02 |
| 2019-12-31 | $508.00M 20-F · filed 2021-01-26 |
| 2018-12-31 | $588.00M 20-F · filed 2020-01-29 |
| 2017-12-31 | $717.00M 20-F · filed 2019-01-30 |
| 2016-12-31 | $521.00M 6-K · filed 2018-01-24 |